Can ruxolitinib reduce splenomegaly in patients with primary or secondary myelofibrosis?

Can Ruxolitinib Decrease Spleen Size in Myelofibrosis?

Yes, ruxolitinib effectively reduces spleen size in patients with myelofibrosis and is recommended as first-line therapy for MF-associated splenomegaly in intermediate-2 or high-risk disease. 1

Evidence Quality and Strength

The European LeukemiaNet guidelines provide high-quality evidence supporting ruxolitinib's benefit in reducing splenomegaly, based on the COMFORT trials which demonstrated a clear dose-response relationship between ruxolitinib and spleen volume reduction 1. The major benefits of ruxolitinib therapy in MF were specifically the reduction in splenomegaly and amelioration of MF-related symptoms 1.

Risk-Stratified Treatment Recommendations

Intermediate-2 or High-Risk Disease

• Ruxolitinib is the recommended first-line approach for MF-associated splenomegaly 1
• This represents a paradigm shift from conventional hydroxyurea as first-line therapy

Intermediate-1 Risk Disease

The approach depends on symptom severity:

• Highly symptomatic splenomegaly (local symptoms or impaired food intake): Use ruxolitinib as first-line therapy 1
• Other intermediate-1 risk patients: Hydroxyurea remains first-line, with ruxolitinib reserved for hydroxyurea-refractory or intolerant cases 1

Low-Risk Disease

• Hydroxyurea is recommended as first-line therapy 1
• Ruxolitinib is appropriate for patients not responding to or intolerant of hydroxyurea 1

Clinical Response Patterns

Real-world evidence demonstrates that ruxolitinib reduces spleen size in the majority of treated patients 2. In the RESPONSE trial for polycythemia vera patients with splenomegaly, 38% achieved ≥35% spleen volume reduction with ruxolitinib versus only 1% with best available therapy 3. Recent data shows that 62.7% of patients had improved spleen size per treating physician assessment 4.

Dosing Considerations and Outcomes

Critical dosing insight: The starting dose significantly impacts outcomes. A large Italian real-world study of 3,494 patients found that those starting at full dose had a median overall survival of 78.2 months versus 52.6 months for reduced-dose initiation 5. However, 66.9% of patients started at reduced doses in real-world practice, often due to baseline cytopenias 5.

Most patients with anemia or thrombocytopenia at diagnosis tolerated and maintained ruxolitinib doses ≥10 mg twice daily for nearly 2 years, with treatment ongoing in 76.1% and rarely discontinued for cytopenias (1.1%) 4.

Common Pitfalls to Avoid

1. Don't delay ruxolitinib in intermediate-2/high-risk disease: The guidelines explicitly recommend it as first-line, not after hydroxyurea failure 1

2. Don't automatically use reduced doses: While platelet count guides initial dosing, the survival disadvantage with reduced-dose initiation suggests optimizing to full dose when feasible 5

3. Don't discontinue prematurely: Median time to spleen response is 3 months 6, so adequate trial duration is essential

4. Recognize ruxolitinib resistance: After 2-3 years, many patients develop resistance despite initial good response 2, requiring consideration of alternative JAK inhibitors or combination strategies

Pre-Transplant Context

For transplant candidates, ruxolitinib effectively reduces splenomegaly pre-transplant, with sequential high-dose ruxolitinib followed by low-dose splenic irradiation showing stepwise spleen reduction and favorable engraftment outcomes 7. Pre-transplant ruxolitinib use appears well-tolerated with 93% overall survival at 1 year post-transplant 8.